Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions

Solid tumors, accounting for around 90% of human cancers, present unique challenges due to antigen heterogeneity, immunosuppressive microenvironments, and limited accessibility for conventional pharmacotherapies. Immunotherapies, particularly engineered immune cell therapies, exploit the immune-tumo...

Full description

Saved in:
Bibliographic Details
Main Author: Ziyad M. Althafar
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1614325/full
Tags: Add Tag
No Tags, Be the first to tag this record!